Aytu BioPharma, Inc.AYTUNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank67
3Y CAGR+6.6%
5Y CAGR+83.8%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+6.6%/yr
vs +8.4%/yr prior
5Y CAGR
+83.8%/yr
Recent deceleration
Acceleration
-1.8pp
Decelerating
Percentile
P67
Within normal range
vs 5Y Ago
21x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 8.02% |
| Q3 2025 | 20.87% |
| Q2 2025 | -8.88% |
| Q1 2025 | -4.30% |
| Q4 2024 | -9.86% |
| Q3 2024 | -2.74% |
| Q2 2024 | 8.89% |
| Q1 2024 | 1.65% |
| Q4 2023 | -19.12% |
| Q3 2023 | -12.12% |
| Q2 2023 | -29.46% |
| Q1 2023 | 7.55% |
| Q4 2022 | 6.62% |
| Q3 2022 | 0.17% |
| Q2 2022 | 0.21% |
| Q1 2022 | -1.44% |
| Q4 2021 | 0.57% |
| Q3 2021 | -15.53% |
| Q2 2021 | 64.57% |
| Q1 2021 | 11.60% |
| Q4 2020 | 0.38% |
| Q3 2020 | -63.79% |
| Q2 2020 | 237.96% |
| Q1 2020 | 41.04% |
| Q4 2019 | 26.61% |
| Q3 2019 | 5.10% |
| Q2 2019 | -8.92% |
| Q1 2019 | 4.64% |
| Q4 2018 | 34.14% |
| Q3 2018 | -2.37% |
| Q2 2018 | -15.42% |
| Q1 2018 | 1.87% |
| Q4 2017 | -1.41% |
| Q3 2017 | 16499.57% |
| Q2 2017 | -99.37% |
| Q1 2017 | 19.71% |
| Q4 2016 | -35.84% |
| Q3 2016 | 82.46% |
| Q2 2016 | 40.52% |
| Q1 2016 | 26.55% |